Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids

Arthritis & Rheumatology
Eli M MiloslavskyRituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group

Abstract

Nonsevere relapses are more common than severe relapses in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but their clinical course and treatment outcomes remain largely unexamined. We undertook this study to analyze the outcomes of patients with nonsevere relapses in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial who were treated with prednisone according to a prespecified protocol. RAVE was a randomized, double-blind, placebo-controlled trial comparing rituximab (RTX) to cyclophosphamide (CYC) followed by azathioprine (AZA) for induction of remission. Patients who experienced nonsevere relapses between months 1 and 18 were treated with a prednisone increase without a concomitant change in their nonglucocorticoid immunosuppressants, followed by a taper. Forty-four patients with a first nonsevere relapse were analyzed. In comparison to the 71 patients who maintained relapse-free remission over 18 months, these patients were more likely to have proteinase 3-ANCAs, diagnoses of granulomatosis with polyangiitis (Wegener's), and a history of relapsing disease at baseline. A prednisone increase led to remission in 35 patients (80%). However, only 13 patients (30%) were able to maintain second remis...Continue Reading

References

Aug 2, 1979·The New England Journal of Medicine·A S FauciS M Wolff
Nov 1, 1992·Arthritis and Rheumatism·G S HoffmanA S Fauci
Oct 1, 1966·The American Journal of Medicine·C B Carrington, A Liebow
Jan 10, 2001·Current Opinion in Rheumatology·D Jayne
Apr 25, 2001·Arthritis and Rheumatism·J H StoneUNKNOWN International Network for the Study of the Systemic Vasculitides (INSSYS)
Jul 4, 2003·The New England Journal of Medicine·David JayneUNKNOWN European Vasculitis Study Group
Jan 28, 2005·The New England Journal of Medicine·UNKNOWN Wegener's Granulomatosis Etanercept Trial (WGET) Research Group
Dec 26, 2008·The New England Journal of Medicine·Christian PagnouxUNKNOWN French Vasculitis Study Group
May 20, 2009·Annals of Internal Medicine·Kirsten de GrootUNKNOWN EUVAS (European Vasculitis Study Group)
Jul 22, 2010·The New England Journal of Medicine·Rachel B JonesUNKNOWN European Vasculitis Study Group
Jul 22, 2010·The New England Journal of Medicine·John H StoneUNKNOWN RAVE-ITN Research Group
Nov 10, 2010·JAMA : the Journal of the American Medical Association·Thomas F HiemstraUNKNOWN European Vasculitis Study Group (EUVAS)
Sep 29, 2011·Arthritis and Rheumatism·Michael WalshUNKNOWN European Vasculitis Study Group
Dec 1, 2011·Annals of the Rheumatic Diseases·Lorraine HarperUNKNOWN EUVAS investigators
Dec 3, 2011·Clinical Journal of the American Society of Nephrology : CJASN·JulieAnne G McGregorPatrick H Nachman
Aug 2, 2013·The New England Journal of Medicine·Ulrich SpecksUNKNOWN RAVE-ITN Research Group
Mar 22, 2014·Medicine·Jason SpringerAlexandra Villa-Forte
Jul 23, 2014·Arthritis & Rheumatology·E M MiloslavskyUNKNOWN Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group
Nov 6, 2014·The New England Journal of Medicine·Loïc GuillevinUNKNOWN French Vasculitis Study Group

❮ Previous
Next ❯

Citations

Feb 18, 2016·Arthritis & Rheumatology·Lynn A FussnerUNKNOWN Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group
Jul 21, 2016·Expert Opinion on Emerging Drugs·David Saadoun, Patrice Cacoub
Jun 25, 2016·Annals of the Rheumatic Diseases·M YatesC Mukhtyar
Jan 15, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Divi CornecUlrich Specks
Dec 7, 2016·Modern Rheumatology·Bénédicte WateletBoris Bienvenu
Jun 18, 2017·Internal and Emergency Medicine·Benjamin Chaigne, Loïc Guillevin
Dec 27, 2016·Frontiers in Immunology·Karolina A ZielińskaPhilippe E Van den Steen
Feb 22, 2017·Autoimmunity Reviews·Alberto R M MartinezMarcondes C França
Dec 6, 2017·Zeitschrift für Rheumatologie·Jan Henrik SchirmerFrank Moosig
Jul 17, 2020·Rheumatology International·Anna MasiakZbigniew Zdrojewski
Apr 16, 2020·Expert Opinion on Biological Therapy·Loïc Raffray, Loïc Guillevin
Feb 6, 2017·Current Rheumatology Reports·Romina I Hassan, Angelo L Gaffo
Jul 7, 2019·Rheumatic Diseases Clinics of North America·Sebastian E Sattui, Robert F Spiera

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Arthritis & Rheumatology
Eli M MiloslavskyRituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group
Arthritis and Rheumatism
Eli M MiloslavskyRituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group
Journal of the American Society of Nephrology : JASN
Duvuru GeethaRituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Cees Kallenberg, Thomas Hauser
© 2021 Meta ULC. All rights reserved